Table 26.

Levels of reimbursement, reported barriers to care from reimbursement policies and costs of treatment [IOF audit]

	Reimbursed (%)	Patient or professional impediment	First-line drugs identified	Average cost (€/year)	Generic alendronate (€/year)
Austria	100	No	Yes	257	174
Belgium	10–20	Yes	Yes	160	123
Bulgaria	25	Yes	No	179	80
Cyprus	100a	No	No	640	327
Czech Republic	50–90	No	Yes	359	187
Denmark	50–90	No	Yes	1269	126
Estonia	50–90	Yes	No	232	171
Finland	40	No	Yes	205	40
France	30–65	Yes	Yes	412	209
Germany	100	No	Yes	619	245
Greece	Part	Yes	No	391	239
Hungary	70–90	Yes	Yes	354	115
Ireland	100a	No	No	570	240
Italy	100	Yes	No	619	294
Latvia	50	No	nr	308	85
Lithuania	50–80	Yes	Yes	409	146
Luxembourg	80–100	No	No	336	109
Malta	0	No	Yes	545	190
Netherlands	100	No	Yes	226	4
Poland	30	Yes	No	581	245
Portugal	69	No	Yes	313	16
Romania	50	Yes	Yes	173	53
Slovakia	90+	No	Yes	401	16
Slovenia	100	No	Yes	234	161
Spain	50–100	Yes	Yes	478	201
Sweden	100	No	Yes	667	27
UK	100	No	Yes	226	13

^aDepending on income; nr not recorded;